Go back

Medical regulators accused of ‘backtracking’ on trial pledges

Groups complain that best-practice guidance appears not to have been shared among national authorities

The leaders of Europe’s medical regulators seem to have reneged on commitments around helping to ensure that the results of clinical trials are made public, various medical groups have complained.

Representatives of five medical groups wrote to the Heads of Medicines Agencies on 21 March, expressing “deep concern” that the HMA—leaders of national medical regulators in the European Economic Area—“appear to have backtracked” on commitments they made in July 2021.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.